Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SyntheMed has announced that Repel-CV, the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery.
Subscribe to our email newsletter
SyntheMed’s Repel-CV will be marketed throughout Canada by Force3 Medicale, a Montreal-based distributor of cardiac surgery products.
The Repel-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the body. Repel-CV represents the first in a series of anti-adhesion products under development that are based on the company’s proprietary polymer technology.
Marc Sportsman, vice president of sales at SyntheMed, said: “We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of Repel-CV.”